WFG Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

WFG Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-21	Closed	-$2K	–	1785
2014 Q4	$2K	Hold	21	–	–	﹤0.01%	1827
2014 Q3	$2K	Hold	21	–	–	﹤0.01%	1848
2014 Q2	$1K	Hold	21	–	–	﹤0.01%	1885
2014 Q1	$1K	Hold	21	–	–	﹤0.01%	1870
2013 Q4	$1K	Sell	21 -29	-58%	-$1.97K	﹤0.01%	2055
2013 Q3	$4K	Buy	+50	New	+$3.32K	﹤0.01%	1777

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WFG Advisors's BMRN Position: Q1 2015 in Review

WFG Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2015, closing a stake of 21 shares — an estimated $2K sold.

WFG Advisors first reported a position in BMRN in Q3 2013 and held it in 6 quarters. The position peaked at $4K in Q3 2013. 378 funds tracked by Wall St. Rank hold BMRN as of Q1 2015.

WFG Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
WFG Advisors sold 21 BioMarin Pharmaceuticals shares in Q1 2015, an estimated $2K.
WFG Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 6 quarters.
WFG Advisors's BioMarin Pharmaceuticals position peaked at $4K in Q3 2013.
378 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2015.

Based on WFG Advisors's 13F filing for Q1 2015, filed 12 May 2015.